查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1748864

氯沙坦市場－全球產業規模、佔有率、趨勢、機會和預測，按來源、應用、地區和競爭細分，2020-2030 年

Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Source, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球氯沙坦市場價值為 7.285 億美元，預計到 2030 年將達到 8.9816 億美元，複合年成長率為 3.75%。氯沙坦是一種血管張力素 II 受體阻斷劑 (ARB)，廣泛用於治療高血壓、心臟衰竭和糖尿病腎病變。其臨床療效、可負擔性和安全性使其在全球各種醫療保健系統中廣泛應用。肥胖、高血壓和第 2 型糖尿病等生活型態相關疾病的負擔日益加重，尤其是在老年人口中，大大增加了對氯沙坦等抗高血壓藥物的需求。此外，大眾對慢性病預防意識的提高、學名藥行業的成長以及可及性治療的推廣，進一步推動了市場擴張。然而，與污染相關的產品召回以及激烈的學名藥競爭導致的持續價格壓力等挑戰削弱了一些製造商的盈利能力。儘管有這些限制，氯沙坦仍然是成熟市場和新興市場心血管治療的主要藥物。

市場概覽
預測期 2026-2030
2024年市場規模 7.285億美元
2030年市場規模 8.9816億美元
2025-2030 年複合年成長率 3.75%
成長最快的領域 合約製造組織
最大的市場 北美洲

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

供應鏈中斷

主要市場趨勢

加強聯合療法研究

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球氯沙坦市場的影響

第5章：全球氯沙坦市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按來源（合約製造組織、內部）
    • 依用途（高血壓、中風、糖尿病腎病變、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美氯沙坦市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲氯沙坦市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區氯沙坦市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲氯沙坦市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲氯沙坦市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：全球氯沙坦市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis International AG
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Aurobindo Pharma Ltd.
  • Torrent Pharmaceutical Ltd.
  • Lupin Ltd.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 7269

The Global Losartan Market was valued at USD 728.50 Million in 2024 and is projected to reach USD 898.16 Million by 2030, growing at a CAGR of 3.75%. Losartan, an angiotensin II receptor blocker (ARB), is extensively prescribed for managing hypertension, heart failure, and diabetic nephropathy. Its clinical efficacy, affordability, and safety profile have contributed to its broad utilization across diverse global healthcare systems. The growing burden of lifestyle-related illnesses such as obesity, hypertension, and type 2 diabetes-especially among aging populations-has significantly bolstered demand for antihypertensive medications like losartan. Additionally, increasing public awareness around chronic disease prevention, the growth of the generic pharmaceutical sector, and the promotion of accessible treatments are further propelling market expansion. However, challenges such as product recalls linked to contamination and sustained pricing pressures due to intense generic competition have tempered profitability for some manufacturers. Despite these constraints, losartan remains a mainstay in cardiovascular therapy across both mature and emerging markets.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 728.50 Million
Market Size 2030USD 898.16 Million
CAGR 2025-20303.75%
Fastest Growing SegmentContract Manufacturing Organizations
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The robust expansion of the global healthcare sector, with annual sales surpassing USD 4 trillion, continues to drive the growth of the losartan market. Key segments such as pharmaceuticals and biotechnology account for over USD 850 billion, while diagnostics and medical technology contribute more than USD 400 billion. As healthcare systems worldwide scale up to meet the rising prevalence of chronic conditions, there is heightened focus on early intervention and long-term management strategies for cardiovascular and renal diseases. This has elevated the demand for effective antihypertensive agents, with losartan positioned as a first-line option due to its efficacy in managing blood pressure and reducing the risk of stroke and kidney damage in diabetic patients. Increased healthcare spending, particularly in developing countries, along with broader access to generics, is further accelerating market growth.

Key Market Challenges

Disruption in Supply Chain

Supply chain disruptions pose a persistent challenge to the global losartan market, impacting the availability and timely distribution of both active pharmaceutical ingredients (APIs) and finished formulations. The production of losartan heavily depends on stable API sourcing, predominantly from manufacturing hubs in India and China. Any disruption caused by regulatory non-compliance, factory shutdowns, environmental restrictions, or geopolitical tensions can lead to delays and shortages. In addition, reliance on limited global suppliers creates bottlenecks, especially during periods of heightened demand. These interruptions not only affect drug availability but can also lead to price fluctuations, undermining supply chain resilience and complicating inventory management for manufacturers and healthcare providers alike.

Key Market Trends

Increasing Research into Combination Therapies

A growing trend shaping the losartan market is the increasing focus on fixed-dose combination therapies for the treatment of hypertension and related cardiovascular disorders. With the complexity of disease management rising, pharmaceutical companies are exploring synergistic formulations that combine losartan with complementary antihypertensive agents such as hydrochlorothiazide or amlodipine. These combination therapies aim to improve therapeutic outcomes, simplify dosing regimens, and boost patient adherence. Inspired by successful models in oncology and other chronic disease areas, this trend is supported by clinical data demonstrating enhanced efficacy and patient satisfaction. Fixed-dose combinations also offer pharmaceutical companies a pathway to differentiate their products in a competitive generic market, helping to extend product lifecycles and align with evolving clinical guidelines that prioritize combination treatment strategies.

Key Market Players

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Novartis International AG
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Aurobindo Pharma Ltd.
  • Torrent Pharmaceutical Ltd.
  • Lupin Ltd.

Report Scope

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Losartan Market, By Source:

  • Contract Manufacturing Organizations
  • In-House

Losartan Market, By Application:

  • Hypertension
  • Stroke
  • Diabetic Nephropathy
  • Others

Losartan Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations

Global Losartan Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Losartan Market

5. Global Losartan Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Source (Contract Manufacturing Organizations, In-House)
    • 5.2.2. By Application (Hypertension, Stroke, Diabetic Nephropathy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Losartan Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Source
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Losartan Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Source
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Losartan Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Source
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Losartan Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Source
        • 6.3.3.2.2. By Application

7. Europe Losartan Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Losartan Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Source
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Losartan Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Source
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Losartan Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Source
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Losartan Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Source
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Losartan Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Source
        • 7.3.5.2.2. By Application

8. Asia Pacific Losartan Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Losartan Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Source
        • 8.3.1.2.2. By Application
    • 8.3.2. India Losartan Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Source
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Losartan Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Source
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Losartan Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Source
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Losartan Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Source
        • 8.3.5.2.2. By Application

9. South America Losartan Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Losartan Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Source
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Losartan Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Source
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Losartan Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Source
        • 9.3.3.2.2. By Application

10. Middle East and Africa Losartan Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Source
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Losartan Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Source
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Losartan Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Source
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Losartan Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Source
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Losartan Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Merck & Co. Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Pfizer Inc.
  • 16.3. Teva Pharmaceutical Industries Ltd.
  • 16.4. Sanofi S.A.
  • 16.5. Novartis International AG
  • 16.6. Dr. Reddy's Laboratories Ltd.
  • 16.7. Sun Pharmaceuticals Industries Ltd.
  • 16.8. Aurobindo Pharma Ltd.
  • 16.9. Torrent Pharmaceutical Ltd.
  • 16.10. Lupin Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer